Discovery MS is a non-profit research initiative housed in the David H. Murdock Research Institute (DHMRI) at the NC Research Campus (NCRC). Discovery MS is accessing the expertise and instrumentation of the DHMRI and raising private research dollars to unlock scientific discoveries to develop new prognostic and diagnostic tools for multiple sclerosis (MS).
The goal of Discovery MS research is to promote fuller, more active lives for people with MS by advancing the understanding of the origins of MS and improving diagnosis, prediction of disease progression, and assessment of treatment efficacy.
Discovery MS evolved from the work of Simon Gregory, PhD. Dr. Gregory is recognized for the 2007 discovery of a genetic connection between the ILR7 gene and MS. He is also the Discovery MS principal investigator as well as the director of DHMRI’s Genomics Laboratory, the principal investigator of three Duke University Kannapolis MS sub-studies, and a professor of neurology at Duke University. Many of the Discovery MS studies use biospecimens donated by the 975 participants of the Duke- Kannapolis MURDOCK MS Study.
Supported by the generous donations of Herman Stone, CEO of Stone Theaters, and the J. Cox Family Foundation, Discovery MS is focused on multiple investigations in collaboration with a global network of scientists that include:
- A new model to distinguish Beta-interferon responders and non-responders. Beta-interferon is a first-line treatment used to slow the progression of MS.
- The development of biomarker signatures to predict the development of MS.
- Gene expression studies in longitudinal samples of patients with primary progressive MS to determine markers and mechanisms of disease progression.
- Novel therapies that moderate immune cell expression, treat inflammation and promote remyelination.
- Development of a smartphone app to track symptoms for presentation to health care providers and to identify signatures of disease progression.
Visit DiscoveryMS.org to learn more.